Federal Reports

The VA Office of Inspector General (OIG) conducted a healthcare inspection to evaluate concerns related to a patient’s response to oxycodone, an opioid pain mediation, including initial post-surgery care and during an acute change in condition (event) at the facility. The OIG also assessed management actions taken by the facility after the event. The OIG found that although providers ordered and nursing staff administered oxycodone consistent with manufacturer’s recommendations, the patient developed signs and symptoms of altered mental status, slowed breathing, and low oxygen in the tissues. The patient was administered naloxone and the symptoms immediately improved. Naloxone has no effect as an antidote in reversing adverse drug event symptoms when given to patients who have not taken opiates. Naloxone’s effectiveness in treating the signs and symptoms supports that the patient was having a response to oxycodone. Providers assessed and treated the patient’s adverse drug event symptoms and the patient did not have further episodes. Facility managers did not consider the patient’s response to oxycodone as one that required a review to determine causative factors and did not report the event to the Veterans Health Administration Adverse Drug Event program or conduct a root cause analysis or an aggregate review. These reviews would have allowed for communication between facility staff and leaders, and patient safety improvement considerations regarding the oxycodone vulnerabilities. The OIG found a clinical disclosure, though warranted, was not documented. An institutional disclosure was conducted approximately six weeks after the event. The Director did not ensure compliance with facility’s peer review policy. In addition, the Surgical Work Group did not meet monthly and meeting minutes lacked discussion of required data. The OIG made six recommendations related to resident supervision; reviewing, capturing and reporting adverse drug events; peer reviews; and documentation of clinical disclosures, and Surgical Work Group meetings.

The OIG investigated an allegation that a supervisor within the Office of the Secretary lowered a subordinate employee’s annual performance rating in reprisal for protected disclosures and activities made by the employee.We found no evidence that the supervisor reprised against the employee. We confirmed that the employee made protected disclosures and engaged in protected activities. However, we found that the supervisor would have given the employee the same performance rating absent the protected disclosures and activities.

The OIG investigated allegations that a former U.S. Fish and Wildlife Service (FWS) assistant hatchery manager directed an FWS biologist to validate an inaccurate cause of death for an endangered fish species in a mortality report to cover up alleged neglect at an FWS fishery. It was also alleged that a culture of censorship existed within that FWS region’s management. We investigated this matter jointly with the U.S. Department of the Interior’s (DOI’s) scientific integrity coordinators, Office of Quality and Science Integrity, U.S. Geological Survey.We found no evidence to corroborate the allegation that the biologist was directed to falsify scientific records, nor did we find evidence to corroborate that she was censored. We determined that the biologist was disciplined for a pattern of discourteous behavior toward management and not, as was claimed, in retaliation for scientific findings that reflected poorly on the FWS.We provided this report to the FWS Director for any action deemed appropriate.

Seek link below for the full report, report summary, multimedia or any agency follow-up.

The Chemical Safety Board (CSB) purchase card program, through which the agency spent $326,859 in FY 2018, is at low risk for unauthorized purchases.